ArticleJournal of gastrointestinal oncology2025
Efficacy and safety of dose adjustment for fruquintinib in the third-line treatment of metastatic colorectal cancer: a retrospective study with real-world settings.
Article in Journal of gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Erratum: Efficacy and safety of dose adjustment for fruquintinib in the third-line treatment of metastatic colorectal cancer: a retrospective study with real-world settings.Journal of gastrointestinal oncology · 2026Article
- New dosing schedules in pre-treated patients with metastatic colorectal cancer.Journal of gastrointestinal oncology · 2025Article
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Fruquintinib, a standard third-line treatment option for metastatic colorectal cancer (mCRC), has been shown to significantly prolong both overall survival (OS) and progression-free survival (PFS) in patients. However, we have observed that the standard dosing of fruquintinib is frequently associated with a higher incidence of adverse effects within the Chinese population, leading some patients-particularly elderly individuals-to be unable to tolerate it. This study presents a retrospective analysis to evaluate the therapeutic efficacy and safety of adjusting the administration frequency of fruquintinib in patients with mCRC. Methods: We conducted a retrospective analysis of the follow-up data and clinicopathological characteristics of 99 patients with mCRC who were treated with an adjusted frequency of furquinitinib administration at our center. We conduct regular imaging follow-ups and tumor marker evaluations to assess the therapeutic efficacy in patients. PFS data are collected through these assessments, while OS and adverse effects information is obtained via structured telephone follow-ups. Results: There were 99 patients with mCRC treated with fruquintinib monotherapy at an adjusted dosing frequency. The median progression-free survival (mPFS) for the 99 patients on fruquintinib monotherapy was 4.1 months and the median overall survival (mOS) was 11.4 months following the adjustment of dosing frequency, the overall response rate (ORR) was 2.0%, and the disease control rate (DCR) was recorded at 40.4% within the fruquintinib monotherapy. Overall, after receiving oral administration of fruquintinib at the modified frequency, no grade 3 or higher adverse reactions occurred in all patients. Conclusions: Our results showed that the administration of fruquintinib at an adjusted dosing frequency has not significantly impacted the efficacy while demonstrating a favorable safety profile. However, this conclusion necessitates further validation through prospective clinical trials with a larger sample size.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.